Dry Eye and Omega-3

From a western clinical standpoint, interest in omega‑3 fatty acids for dry eye disease (DED) stems from their anti‑inflammatory properties and potential to improve the tear film’s lipid layer. EPA and DHA, the long‑chain omega‑3s found in marine sources, are precursors to resolvins and protectins—lipid mediators that actively resolve inflammation. In DED, where cytokine activity, matrix metalloproteinases, and meibomian gland dysfunction (MGD) contribute to symptoms and ocular surface damage, these mechanisms are biologically plausible. Smaller randomized trials have reported improvements in dry eye symptoms (OSDI), tear break‑up time, and tear osmolarity after several weeks to months of supplementation, with some studies noting better meibum quality—suggesting benefit may be greatest in evaporative DED linked to MGD. However, the evidence is not uniform. The large, rigorously conducted DREAM trial found no superiority of fish‑derived omega‑3s over an olive‑oil placebo at 12 months. Several factors complicate interpretation: choice of placebo (olive oil may itself have mild anti‑inflammatory effects), variability in formulations (ethyl ester vs triglyceride vs re‑esterified triglyceride), wide dosing ranges, adherence, baseline diet, and heterogeneity of DED phenotypes. Systematic reviews and meta‑analyses generally show modest improvements but consistently highlight these methodological issues and the risk of bias in smaller studies. Expert guidelines (TFOS DEWS II; AAO) therefore categorize omega‑3s as a possible adjunct, with the caveat that expectations should be modest and that benefits may be more likely in evaporative/MGD cases than in aqueous‑deficient or autoimmune forms (e.g., Sjögren’s). In practice, clinicians emphasize comprehensive care: eyelid hygiene and warm compresses for MGD, preservative‑free lubricants, environmental and screen‑time modifications, management of comorbid blepharitis/rosacea, and when needed, prescription anti‑inflammatories (cyclosporine, lifitegrast) or device‑based therapies (thermal pulsation). Within this framework, discussing dietary patterns rich in omega‑3s is reasonable for general health, and supplements may be considered on a case‑by‑case basis. Markers of benefit, when observed, typically appear within 8–12 weeks and include improved OSDI scores, increased TBUT, reduced tear osmolarity, and fewer MMP‑9–positive results. Safety considerations include gastrointestinal upset, fishy aftertaste, potential interaction with anticoagulants and antiplatelets, and a small signal for atrial fibrillation at higher doses in cardiovascular trials. Shared decision‑making, phenotype‑guided therapy, and monitoring remain central.

Traditional and integrative frameworks approach dry eye through the lens of systemic balance. In Traditional Chinese Medicine (TCM), dry eye is often attributed to yin deficiency of the Liver and Kidney with superimposed wind‑heat drying the ocular surface. Treatment principles include nourishing yin, enriching fluids, and clearing heat. Diets that incorporate nourishing, unctuous foods—conceptually aligned with omega‑3–rich fish and seeds—fit this framework, though classical texts do not specify EPA/DHA per se. Acupuncture at ocular and systemic points aims to modulate qi and blood flow, supporting lacrimal and meibomian function. Emerging clinical studies suggest acupuncture can improve symptoms and tear stability compared with artificial tears in some patients, though methodological quality varies. Ayurveda similarly interprets dry eye as a predominance of vata (dry, light, mobile) and pitta (hot, sharp) qualities. Interventions favor internal and external oleation (snehana) to counter dryness and calm heat. Ghee‑based therapies and dietary guidance to include healthy oils are cornerstones, implemented under trained supervision. Within this paradigm, omega‑3–containing foods are consonant with building ojas (vitality) and soothing inflamed tissues. Naturopathic and integrative clinicians often synthesize these views with modern nutrition science, emphasizing whole‑food sources of omega‑3s, attention to sleep and stress (which can exacerbate ocular surface inflammation), and gentle eyelid self‑care. While direct evidence tying traditional diets or herbal formulas that are rich in omega‑3s to measured improvements in DED is limited, the philosophical alignment is notable: reduce internal heat/inflammation, nourish fluids, and protect surface barriers. This harmonizes with western mechanistic data on resolvins and meibum quality. Clinically, integrative care pairs nonpharmacologic measures—blink training, humidification, mindful screen habits, acupuncture—with nutrition tailored to the individual’s constitution, medical history, and preferences (including algae‑based omega‑3s for those avoiding fish). Safety is emphasized: sourcing high‑quality oils, avoiding rancidity, and coordinating with medical providers when anticoagulants, arrhythmias, pregnancy, or upcoming surgery are present. The shared goal across traditions is durable symptom relief by restoring a stable, well‑nourished ocular surface.